CBP Confirms Finding of Evasion of Duties on Imported Glycine by Shari Pharmachem
CBP has issued a formal notice of determination against U.S. importer Shari Pharmachem USA under the Enforce and Protect Act for allegedly evading antidumping and countervailing duty orders when it imported glycine from China. CBP says evidence shows that Shari Pharmachem USA transshipped Chinese-origin glycine through India.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
As a result of this action, CBP said it will suspend liquidation of any relevant unliquidated entries subject to this investigation; rate adjust and change to entry type 03 those entries that are subject to this investigation and suspend liquidation; and reject any entry summaries and require a re-file for aforementioned entries within the entry summary rejection period.
The proceeding against Shari Pharmachem began when Chicago-area chemicals manufacturer Geo Specialty Chemicals initially filed an EAPA allegation Shari Pharmachem in September 2023 for allegedly evading AD/CVD duties, according to CBP’s notice of determination, released last week. According to shipping data provided by Geo Specialty Chemicals, the glycine may have been transshipped via India as Global Merchants in India does not produce glycine at its facilities, CBP said.
In November 2023, the Trade Remedy Law Enforcement Directorate within CBP’s Office of Trade initiated its investigation, asking Shari Pharmachem to provide entry-related documentation proving the origin of glycine. Shari Pharmachem responded, but the provided information was insufficient, according to CBP. Two suppliers of the merchandise had also indicated later in the proceeding that the glycine may be of Chinese origin, CBP said.